656 related articles for article (PubMed ID: 27367749)
1. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
2. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
[TBL] [Abstract][Full Text] [Related]
3. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
4. The impact of manufacturer coupon use in the statin market.
Daugherty JB; Maciejewski ML; Farley JF
J Manag Care Pharm; 2013; 19(9):765-72. PubMed ID: 24156645
[TBL] [Abstract][Full Text] [Related]
5. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
7. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
8. US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.
Rome BN; Tessema FA; Kesselheim AS
JAMA Intern Med; 2020 Sep; 180(9):1165-1172. PubMed ID: 32897384
[TBL] [Abstract][Full Text] [Related]
9. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
10. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
11. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
12. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
13. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
14. Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin.
Warraich HJ; Salami JA; Khera R; Valero-Elizondo J; Okunrintemi V; Nasir K
JAMA Intern Med; 2018 May; 178(5):719-721. PubMed ID: 29525818
[TBL] [Abstract][Full Text] [Related]
15. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.
Kesselheim AS; Franklin JM; Kim SC; Seeger JD; Solomon DH
J Gen Intern Med; 2015 Nov; 30(11):1633-8. PubMed ID: 25855479
[TBL] [Abstract][Full Text] [Related]
16. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
17. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387
[TBL] [Abstract][Full Text] [Related]
19. Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database.
Liou WS; Hsieh SC; Chang WY; Wu GH; Huang HS; Lee C
Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):752-9. PubMed ID: 23625864
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of compliance and cost effectiveness between brand-name statins and generic statins].
He L; Du X; Wang WH; Ma CS
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Nov; 41(11):1900-1904. PubMed ID: 33297658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
